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Abstract
Cervical dysplasia is a premalignant lesion associated with human papillomavirus (HPV) infection
which, over time, can turn cancerous. Previous studies have indicated that loss of gap junctions may
be a feature of cervical cancer and premalignant dysplasia. Loss of the gap junction protein
connexin43 has been demonstrated in dysplastic cervix, but other connexins have not been
investigated. In contrast we previously showed that HPV-associated cutaneous warts – and other
hyperproliferative skin conditions – display a dramatic upregulation of certain connexins, in
particular connexin26. By performing immunofluorescence staining after antigen retrieval of
paraffin-embedded cervical tissue samples, this study reports for the first time that connexin26 and
connexin30, in addition to connexin43, are expressed in differentiating cells of normal human
cervical epithelia. Moreover, in dysplastic ectocervix, all connexins studied display a dramatic loss
of expression compared to adjacent normal epithelia. The role of connexins in keratinocyte
differentiation and carcinogenesis is discussed.
Findings
Connexins, a family of 20 trans-membrane proteins in
humans, comprise the main subunits of gap junctions –
specialised clusters of intercellular channels that allow
adjacent cells to directly share ions and hydrophilic mol-
ecules of up to ~1 KDa in size [1]. Gap junctional intercel-
lular communication (GJIC) is thought to control tissue
homeostasis and to coordinate cellular processes such as
proliferation, migration and differentiation. Disruption
of GJIC or mutations in connexins is associated with sev-
eral human diseases such as hearing loss, neuropathies
and various skin conditions [2].
There is also substantial evidence that connexins have a
tumour suppressor role [reviewed in [3]]. While reduced
or aberrant GJIC or connexin expression has been found
in some tumours and in many tumour cell lines [4-7], res-
toration of GJIC in tumour cell lines by connexin
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transfection can reduce growth and tumourigenicity [8-
10]. However, the tumour suppressive effects may be tis-
sue and connexin-specific [11,12] and also appear to
involve non-gap junctional properties of connexins [13-
15]. Moreover, it has been observed that connexin expres-
sion (especially connexin26) is often upregulated in
hyperplastic tissues including psoriatic epidermis and
viral warts [16], benign prostatic hyperplasia [17], and
mouse papillomas [18]. While induction of connexin26
and connexin43 has also been observed in metastatic
breast carcinomas [19], others have reported that
connexin26 and connexin43 are downregulated in mam-
mary carcinoma cell lines and re-expression of these con-
nexins leads to repression of tumour-forming ability [20].
Although potent tumour promoters markedly downregu-
late GJIC in cultured cells [21], intact skin painted with
tumour promoters such as 12-O-tetradecanoylphorbol
13-acetate (TPA) show a dramatic upregulation of
connexin26 and connexin43 expression [22-24]. Moreo-
ver, several reports have shown a negative correlation
between expression of connexins and cell diapedesis and
or tumour metastasis, including brain tumours [25,26],
melanoma [27], breast carcinoma [28] and lung squa-
mous cell carcinomas [29]. Thus, although connexins act
as tumour suppressor genes in several types of cancers, the
role of connexins in metastasis are more conflicting.
The association of certain "high risk" human papillomavi-
ruses (HPVs) with the development of cervical cancer on
the other hand has been clearly demonstrated [30], with
several targets and functions of the viral oncoproteins
identified [31]. However, tumour progression only occurs
in a very small subpopulation of HPV infected individu-
als; thus, it is thought that several molecular and cellular
changes are required over time for malignant conversion
to take place. One of these cellular changes may be loss of
connexin expression and/or GJIC. Indeed, it was observed
more than four decades ago, using freeze-fracture electron
microscopy, that normal cervix has abundant gap junc-
tions, and that these are deficient in cervical carcinomas
[32]. Further work also demonstrated a dramatic decrease
of gap junction plaques in pre-malignant conditions such
as severe dysplasia [33]. More recently, immunohisto-
chemistry of cervical biopsies showed reduced
connexin43 expression in dysplastic regions compared to
normal epithelia [34] and work in-vitro has suggested that
loss of GJIC may be an early event in papillomavirus asso-
ciated cell transformation [35-38]. However, this may be
limited to certain cell types or to particular oncogenes that
are not always expressed during tumour progression (for
example the E5 oncogene product that is frequently
deleted after viral integration). Recently, we also showed
that human cervical keratinocytes harbouring HPV-16
expressed several connexins (including connexin26,
connexin30 and connexin43), and displayed extensive
GJIC that was only lost at a late malignant stage [39]. This,
together with our observation of a dramatic upregulation
of connexin26 expression in cutaneous HPV warts [16],
prompted us to investigate the expression pattern of sev-
eral connexins in normal and dysplastic cervical epithelia.
Six duplicate slides of HPV-16 positive dysplastic cervix
(cervical intraepithelial neoplasia (CIN) I, CIN I/II, and
CIN III) were obtained from Dr. John Doorbar (Dr Karl
Sotlar Institute for Pathology, Tubingen Germany, as pre-
viously described [40]). Antigen retrieval using pressure
cooking in citrate buffer was performed followed by
immunofluorescence staining using antibodies and meth-
ods as previously described [39]. All antibodies were
diluted in PBS containing 1% bovine serum albumin
(BSA), 0.1% Tween-20 and 0.01% SDS, and incubated
overnight at 4°C. The presence of BSA and SDS was used
to improve the connexin staining as previously shown for
other antibodies [41]. Sections were mounted with
Vectashield mounting medium containing DAPI and all
images were obtained using an upright Zeiss Axioplan 2
fluorescence microscope. After immunofluorescence
imaging the slides were washed and stained with Haema-
toxylin and Eosin (H&E) to verify previous CIN gradings.
As seen in Figure 1A, all sections of normal ectocervix
expressed connexin43 (red) mainly in the suprabasal
spinous layers. Some staining was also seen in the basal
layer although it was difficult to identify specific gap junc-
tion plaques. Connexin26 and connexin30 were found
mainly in the upper spinous layers, but some was also
detected in the lower layers similar to connexin43, partic-
ularly with connexin30 (1A and 1B). Overlapping co-
localisation (yellow gap junction plaques) was seen in
connexin26/connexin43 triple-immunofluorescence
staining experiments (Figure 1A) as observed in palmo-
plantar skin [42]. The more differentiated cervical squa-
mes were negative for all three connexins. Moreover, no
definite connexin membrane plaques could be identified
in the basal layer although some gap junction plaques are
likely to be present as previously shown in early freeze-
fracture electron microscopy studies [32,33]. As expected,
the proliferation marker Ki-67 was detected in basal or
suprabasal keratinocytes but not in differentiated cells
(Figure 1B).
In contrast, all sections of dysplastic cervix displayed loss
of protein expression of all three connexins investigated
(Figure 1C–F). Connexin26 and connexin30 expression
was completely absent in the CIN3 lesions (Figure 1C). In
some areas however, particularly using high magnifica-
tion power and high laser exposure, some connexin43
plaques could be seen in dysplastic areas, although it was
difficult to assess accurately the dysplasia in those exact
areas (Figure 1D–E). Some small connexin30 gapMolecular Cancer 2005, 4:31 http://www.molecular-cancer.com/content/4/1/31
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Connexin expression in normal and dysplastic human cervical epithelium Figure 1
Connexin expression in normal and dysplastic human cervical epithelium. All nuclei are stained with DAPI (blue). A: 
All normal ectocervical tissue sections revealed positive staining of connexin43 gap junctions (red) particularly in the spinous 
layers. Connexin26 was also positive (green), particularly in upper spinous and more superficial layers. Overlapping expression 
of connexin43 and connexin26 was observed (yellow) and these areas displayed particularly large gap junction plaques (arrow). 
B: Connexin30 (red) displayed a similar staining pattern to Connexin26 although gap junction plaques were more frequently 
observed in lower spinous layers (arrow). In these normal sections, the proliferation marker Ki-67 was detected (turquoise) in 
basal and immediate suprabasal layers only, as expected. (C) In all premalignant CIN III sections there was complete absence of 
connexin26 (green) and connexin30 (red). D: In one CIN III lesion, small amounts of connexin43 (red) were present, mainly as 
diffuse cytoplasmic staining, but no positive connexin26 staining was detectable (green). E: In CIN I/II lesions no clear 
connexin26 gap junctions were present (green) whereas several connexin43 plaques were visible (arrow), but in a less homog-
enous fashion compared to normal ectocervix. F: Connexin30 gap junctions were clearly detected in areas of low grade CIN I 
lesions, although they tended to occur in stratified regions of cell differentiation (arrow) rather than areas of abnormal cellular 
proliferation (Ki-67, turquoise) and atypical cellular crowding.
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junction plaques were also identified in dysplastic tissue,
but generally these appeared separate from cells positive
for the proliferation marker Ki-67 in stratified cells of dys-
plastic cervix (Figure 1F). Thus, although some
connexin30 and connexin43 gap junction plaques were
occasionally seen in low grade CIN I/II cervical biopsies,
there was always a dramatic loss of connexin expression
compared to adjacent normal tissue.
In conclusion, this report demonstrates for the first time
the presence of connexin26 and connexin30 gap junction
plaques, as well as connexin43, in human ectocervix, dis-
playing a similar staining pattern to that observed for
connexin26 in vaginal epithelium [16]. Moreover, dys-
plastic areas of the biopsies show a dramatic loss of gap
junction plaques, primarily due to reduced expression
rather than cytoplasmic accumulation of connexin pro-
teins. However, it cannot be excluded that cytoplasmic
connexins are undetectable by the current staining proto-
col and antibodies available. The use of paraffin embed-
ded tissue may reduce the detection efficiency of smaller
gap junction plaques and/or cytoplasmic proteins. Some
general background immunofluorescence is present in
both normal and dysplastic tissue and this also hampers
detection of cytoplasmic proteins. Significantly however,
lack of staining in dysplastic lesions cannot be attributed
to sample or patient factors, as the staining of both nor-
mal and dysplastic tissue were performed using the same
tissue biopsies. It thus also appears that the lack of gap
junctions in CIN lesions are likely to be controlled in an
intracrine fashion rather than as an effect of paracrine or
hormonal fashion, particularly since areas of gap junction
plaques where observed in differentiating cells layered in
between dysplastic/Ki-67 positive cells. Currently very lit-
tle is known regarding how connexin gene expression is
regulated and further studies, perhaps using laser capture
followed by RT-PCR and/or methylation specific PCR, are
required to elucidate what regulates the overexpression
and loss of connexins, in cutaneous warts and CIN lesions
respectively. Our previous work on model cell lines indi-
cate that a combination of cytoplasmic connexin accumu-
lation and loss of connexin transcription may occur [39].
Expression of connexin26 but not connexin40 and
connexin43 has been shown to reduce tumourigenesis of
HeLa cells (cervical tumour cells) [12]. It is also likely that
other connexins are expressed in human ectocervix, for
example connexin31 which is expressed in differentiating
keratinocytes in the epidermis [43], and may play a differ-
ent role in epidermal biology and carcinogenesis. In order
to answer some of these outstanding questions, it is
imperative to decipher more accurately what biological
role gap junctions and individual connexins execute.
These results are clearly in disparity to observations in
interfollicular epidermis, where connexin26 and
connexin30 are normally not present (apart from palmo-
plantar skin) but becomes highly expressed in areas of
hyperproliferation such as viral warts [16]. The reason for
this remains unknown, but several factors may contribute.
For example, the stratifying cervical epithelium is of non-
keratinising nature. Unlike dysplastic cervical epithelia,
cutaneous warts are typically highly proliferative, thick
lesions, and there is some evidence that the presence of
gap junctions may favour such stratification (perhaps due
to metabolic co-operation) [39]. Conversely, it is cur-
rently difficult to explain why gap junctions are lost in
HPV-16 positive CIN lesions. It is clear however that basal
keratinocytes express at least tenfold fewer gap junction
plaques than differentiated keratinocytes [32,33], and the
lack of gap junctions in CIN lesions may simply reflect
failure of keratinocyte differentiation in the stratified lay-
ers. Although there is some evidence, it remains to be seen
whether connexins themselves play a direct role in regu-
lating keratinocyte differentiation. Loss of connexin
expression may also be associated with HPV infection,
although our recent results suggests that such correlation
requires high levels of oncogene expression and/or a fur-
ther malignant progressed state [39]. A viral advantage
associated with loss of GJIC has not been described, how-
ever a recent intriguing report has documented gap-junc-
tion-mediated immunological coupling allowing direct
transfer of antigenic peptides [44] which may be involved
in ensuring proper antigenic T-cell response against
viruses such as HPV hiding in cells or expressing anti-
apoptotic proteins.
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